Original Source(s)
Related Content
Chemoimmunotherapy Linked to HNSCC Response
Higher pathologic response rates with chemoimmunotherapy versus immunotherapy alone call for phase 3 trials, but survival implications remain unknown.
June 5, 2026
-
6 min
FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI
The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.
June 15, 2026
-
3 min
Top 10 Growing Metro Areas With Active HPSAs
These 10 metropolitan areas reported population gains and active federal shortage area designations identified in census and health care workforce data.
June 30, 2026
-
3 min
